10% original issue discount 5% Senior Convertible NOTE DUE february 26, 2020OncBioMune Pharmaceuticals, Inc • July 18th, 2019 • Pharmaceutical preparations • New York
Company FiledJuly 18th, 2019 Industry JurisdictionTHIS 10% SENIOR CONVERTIBLE NOTE is one of a series of duly authorized and validly issued 5% Senior Convertible Notes issued at a 10% original issue discount by OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”) (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 18th, 2019 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
Contract Type FiledJuly 18th, 2019 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of June 26, 2019, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and [ ] (the “Purchaser”).
COMMON STOCK PURCHASE WARRANT OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals, Inc • July 18th, 2019 • Pharmaceutical preparations
Company FiledJuly 18th, 2019 IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to shares of Common Stock (subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).